| SEC For   | m 4<br>FORM   | 4  | UNITED  | ) STA   | TES  | s se   |  |     | ES AND   |                    | NGE C   | COMM                                   | SSION   |   |               |  |   |
|---|---|--|---|---------|--|--|--|-----|--|--------------------|---|--|---|---|---------------|--|---|
| Section 16. Form 4 or Form 5<br>obligations may continue. See                                 |   |  |   | d purs  | Washington, D.C. 20549<br><b>NT OF CHANGES IN BENEFICIAL OWNERSI</b><br>d pursuant to Section 16(a) of the Securities Exchange Act of 1934<br>or Section 30(h) of the Investment Company Act of 1940 |  |  |     |  |                    |   |  | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 |   |               |  |   |
| 1. Name and Address of Reporting Person*<br>Wilms Joris                                       |   |  |   |         |  | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>Y-mAbs Therapeutics, Inc.</u> [ YMAB ]  |  |     |  |                    |   |  | 5. Relationship of Reporting<br>(Check all applicable)<br>Director                  |   |               | 10% Owner  |   |
| (Last) (First) (Middle)<br>C/O Y-MABS THERAPEUTICS, INC.<br>230 PARK AVENUE SUITE 3350        |   |  |   |         |  | 3. Date of Earliest Transaction (Month/Day/Year)<br>12/15/2020   |  |     |  |                    |   |  |   | X below) below) SVP & CCO   |               |  |   |
| (Street)<br>NEW YORK NY 1010  |   |  |   |         | 4.1  | 4. If Amendment, Date of Original Filed (Month/Day/Year)<br>5. Individual or Joint/Group F<br>Line)<br>X Form filed by One F<br>Form filed by More<br>Person |  |     |  |                    |   |  |   |   |               |  |   |
| (City)  | (S  |  | (Zip)   | -Deriv  | ativ   | e Se   | curities   |     | ouired D                                       | isnosed (          | of or Be  | neficial                               |   |   |               |  |   |
| Table I - Non-Deriva       1. Title of Security (Instr. 3)     2. Transa<br>Date<br>(Month/D) |   |  |   |         | action   | ction 2A. Deem<br>Execution  |  |     | 3. 4. Securi<br>Transaction<br>Code (Instr. 5) |                    | ities Acquired (A) d<br>d Of (D) (Instr. 3, 4   |  | 5. Amou<br>Securitie<br>Beneficia   | nt of<br>s<br>ally<br>following   | Form<br>(D) o | orm: Direct<br>)) or Indirect<br>) (Instr. 4)                            | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |   |  |   |         |  |  |  |     | Code V   | Amount             | (A) o<br>(D)  | r Price                                | Transact<br>(Instr. 3 a   | ion(s)  |               |  |   |
|   |   |  |   |         |  |  |  |     | uired, Dis<br>5, options                       |                    |   |  | Owned   |   |               |  |   |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution I<br>if any<br>(Month/Day | Date, T | ransa<br>Code (l   |  | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr.<br>3, 4 and 5) |     | 6. Date Exer<br>Expiration D<br>(Month/Day/    | ate                | 7. Title and Am<br>of Securities<br>Underlying<br>Derivative Secu<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)                                 | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s<br>(Instr. 4) |               | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4)                             |
|   |   |  |   |         | Code   | v  | (A)  | (D) | Date<br>Exercisable                            | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares | er  |   |               |  |   |
| Employee<br>Stock<br>Option<br>(right to<br>buy) <sup>(1)</sup>                               | \$53.88   | 12/15/2020                                 |   |         | A  |  | 20,000   |     | (2)  | 12/15/2030         | Common<br>stock   | 20,000                                 | \$0   | 20,00   | )0            | D  |   |

## Explanation of Responses:

1. Stock options granted to the Reporting Person pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.

2. The stock option shall vest and become exercisable as to 25% of the shares subject to the option on December 15, 2021, and thereafter vests and become exercisable as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

<u>/s/ Joris Wilms</u>

\*\* Signature of Reporting Person Date

<u>12/16/2020</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.